Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
VTGN
#4002
Vistagen Therapeutics, Inc. Common Stock
0.607
3
USD
-3.73%
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
-3.73%
Monthly Change
+17.90%
6 month change
+17.90%
Year Change
+17.90%
Previous Close
0.630
8
Open
0.607
3
Bid
0.607
3
Ask
0.610
3
Low
0.607
3
High
0.607
3
Volume
6
Markets
US Stock Market
Healthcare
VTGN
Open full chart
Financials
Overview
Statement
Statistics
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
6.38 M
6.89 M
7.87 M
27.03 M
29.16 M
—
Valuation ratios
Enterprise value
—
—
—
26.74 M
5.76 M
74.42 M
Price to earnings ratio
—
—
—
-3.55
-1.5
-4.82
Price to sales ratio
—
—
—
98.23
158.83
443.43
Price to cash flow ratio
—
—
—
-4.05
-1.83
-5.63
Price to book ratio
—
—
—
0.91
1.1
1.81
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.17
0.64
2.81
0.24
0.61
0.91
Return on equity %
0.19
0.74
4.9
0.26
0.73
1.12
Return on invested capital %
1 363.97
3 390.02
4 642.81
2 867.66
4 598.63
5 050.58
Gross margin %
100
100
100
100
100
400
Operating margin %
1 646.06
4 308.3
26.11 K
3 103.48
11.52 K
96.99 K
EBITDA margin %
—
—
—
—
—
—
Net margin %
1 646.09
4 306.76
26.1 K
2 759.59
10.58 K
91.71 K
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
24.85
12.32
3.83
23.55
6.51
22.95
Inventory turnover
—
—
—
—
—
—
Asset turnover
0.02
0.01
0
0.01
0
0.01
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
0
—
—
0
—
—
Long term debt to total equity ratio
0
—
—
0
—
—
Per share metrics
Operating cash flow per share
—
-6.86
-7.14
1.33
1.36
1.72
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
—
10.32
2.39
6.16
2.61
8.21
Net current asset value per share
—
10.76
2.52
6.23
2.66
8.45
Tangible book value per share
—
9.81
1.74
5.9
2.28
7.12
Working capital per share
—
9.88
1.86
5.97
2.25
6.99
Book value per share
—
9.81
1.74
5.9
2.28
7.12
News
Vistagen Therapeutics reduces workforce by 20 percent to manage costs
VistaGen at TD Cowen Conference: Pherine Platform in Focus
Vistagen Therapeutics, Inc. (VTGN) Q3 2026 Earnings Call Transcript
Earnings call transcript: VistaGen Therapeutics Q3 2026 highlights AI-driven trial analysis
VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Lags Revenue Estimates
Vistagen Therapeutics reports Phase 3 trial for fasedienol did not meet endpoint
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.47%
Jefferies downgrades VistaGen stock rating to Hold on failed Phase III trial
VistaGen stock rating downgraded by William Blair after trial miss
Stifel downgrades VistaGen stock to Hold as anxiety drug fails in trial
Vistagen stock plummets after failed anxiety treatment trial
Vistagen’s anxiety treatment fails to meet primary endpoint in trial